Posted by Michael Wonder on 30 Oct 2021
FDA approves Novartis Scemblix (asciminib) with novel mechanism of action for the treatment of chronic myeloid leukemia
29 October 2021 - Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukaemia who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor treatments.
Novartis announced today that the US FDA approved Scemblix (asciminib) for the treatment of chronic myeloid leukemia in two distinct indications.
